Impax Asset Management Group’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $14.5M | Buy |
115,000
+15,000
| +15% | +$1.89M | 0.08% | 119 |
|
|
2025
Q1 | $11.1M | Sell |
100,000
-161,599
| -62% | -$17.9M | 0.07% | 136 |
|
|
2024
Q4 | $35.7M | Buy |
261,599
+176,599
| +208% | +$24.1M | 0.16% | 96 |
|
|
2024
Q3 | $9.79M | Buy |
85,000
+35,000
| +70% | +$4.03M | 0.04% | 166 |
|
|
2024
Q2 | $6.88M | Hold |
50,000
| – | – | 0.03% | 196 |
|
|
2024
Q1 | $6.9M | Sell |
50,000
-60,000
| -55% | -$8.28M | 0.03% | 199 |
|
|
2023
Q4 | $14.5M | Sell |
110,000
-25,000
| -19% | -$3.29M | 0.06% | 140 |
|
|
2023
Q3 | $15.2M | Sell |
135,000
-65,000
| -33% | -$7.31M | 0.07% | 131 |
|
|
2023
Q2 | $18.9M | Hold |
200,000
| – | – | 0.08% | 126 |
|
|
2023
Q1 | $20.2M | Buy |
200,000
+25,000
| +14% | +$2.53M | 0.08% | 125 |
|
|
2022
Q4 | $20.9M | Buy |
175,000
+25,000
| +17% | +$2.99M | 0.09% | 122 |
|
|
2022
Q3 | $15.9M | Buy |
+150,000
| New | +$15.9M | 0.08% | 128 |
|
|
2020
Q2 | – | Sell |
-75,000
| Closed | -$6.49M | – | 289 |
|
|
2020
Q1 | $6.49M | Buy |
+75,000
| New | +$6.49M | 0.09% | 130 |
|
|
2019
Q4 | – | Sell |
-22,000
| Closed | -$1.98M | – | 295 |
|
|
2019
Q3 | $1.98M | Buy |
+22,000
| New | +$1.98M | 0.03% | 190 |
|